Short talks Pharmacology 18
Disease models, drug development

Programme

• 09:00 – 09:15 10 Min. 5 Min.

  • Oral presentation
  • 82

  Topical application of inhaled macrophage-specific carbohydrate-coupled antimiR-21 attenuates pulmonary inflammation and fibrosis – two hallmarks of COVID-19.

  • Christina Beck (München / DE)

   Disease models, drug development, Drug transport/delivery and metabolism
• 09:15 – 09:30 10 Min. 5 Min.

  • Oral presentation
  • 83

  In vivo microRNA activity sensing of the mammalian heart at single-cell resolution reveals selective uptake of antisense oligonucleotides by injured cardiomyocytes

  • Petros Avramopoulos (Munich / DE)

   Disease models, drug development, Drug transport/delivery and metabolism
• 09:30 – 09:45 10 Min. 5 Min.

  • Oral presentation
  • 84

  From bioinformatic profiling to the development of siRNA-loaded nanoparticle-based therapy against lung fibrosis

  • Mandy Otto (Hannover / DE)

   Disease models, drug development, Drug transport/delivery and metabolism
• 09:45 – 10:00 10 Min. 5 Min.

  • Oral presentation
  • 85

  Cardioprotective MicroRNAs (ProtectomiRs) as potential novel cardioprotective therapeutics for acute myocardial infarction

  • Paula Luise Wiederanders (Tîrgu Mureş / RO)

   Cardiac pharmacology, Disease models, drug development
• 10:00 – 10:15 10 Min. 5 Min.

  • Oral presentation
  • 86

  A chronic lung infection model with P. aeruginosa for evaluation of novel anti-infectives

  • Katharina Rox (Braunschweig / DE)

   Disease models, drug development, Immunopharmacology / inflammation / anti-infectives